A case report of a patient with a live born child from the 14th pregnancy after 13 spontaneous abortion, diagnosed with systemic lupus erythematosus and antiphospholipid syndrome
PDF BG/EN

Keywords

antiphospholipid syndrome
pathological pregnancy
spontaneous abortion
systemic lupus erythematosus

How to Cite

[1]
Stoilov, N. and Boyadzhieva, V. 2019. A case report of a patient with a live born child from the 14th pregnancy after 13 spontaneous abortion, diagnosed with systemic lupus erythematosus and antiphospholipid syndrome. Revmatologiia (Bulgaria). 27, 4 (Dec. 2019), 55-62. DOI:https://doi.org/10.35465/27.4.2019.pp55-62.

Abstract

Abstract. Antiphospholipid syndrome is a systemic autoimmune disease with unclear etiology and complex pathogenesis. It can be a single nosological unit or in the context of another systemic disease of the connective tissue – most commonly systemic lupus erythematosus (SLE). The presence of antiphospholipid antibodies in pregnant women is associated with an increased rate of complications during pregnancy. The most common symptoms are preeclampsia and eclampsia, early spontaneous abortions and late fetal loss, in the absence or presence of a proven genetic defect for congenital thrombophilia and/or chromosomal diseases. A multidisciplinary approach and regular patient consultations are key factors in the follow-up and positive outcomes of pregnancy in women with SLE and antiphospholipid syndrome (APS). Timely treatment with corticosteroids, anticoagulants, antiаggregant agents, and intravenous immunoglobulins repeatedly increases the chance of successful completion of pregnancy with live birth.
https://doi.org/10.35465/27.4.2019.pp55-62
PDF BG/EN

References

  1. Stoilov N, Rashkov R, Stoilov R. Antiphospholipid syndrome – historical data, etiology and pathogenesis. Revmatologiia. 2011;19(4);26-33.
  2. Stoilov N, Zdravkova Ya, Rashkov R. Antiphospholipid syndrome – antibodies and clinico-immunological correlations. Revmatologiia. 2013;2(1);20-30.
  3. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/ antithrombin III cofactor activity by anticardiolipin antibodies: A mechanism for thrombosis. Thromb. Res. 1993;71;103-111.
  4. Rashkov R, Yoneva Ts, Zdravkova Ya et al. Clinical and immunological characteristics of systemic lupus erythematosus and their relation to disease activity – data of the Bulgarian SLE registry. Revmatologiia 2014;22(3-4);25-37.
  5. Ames PR, Tommasino C, D‘Andrea G et al. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies prevalence and significance. Thromb Haemost. 1998;79: 46-49.
  6. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/ antithrombin III cofactor activity by anticardiolipin antibodies: A mechanism for thrombosis. Thromb. Res. 1993;71;103-111.
  7. Lozier J, Takashi N, Putnam W. Complete aminoacid sequences of human plasma b2-glycoprotein I. Proc. Natl. Acad. Sci.USA. 1984;81;3640-3644.
  8. Polz E, Kostner GM. The binding of b2GPI to human serum lipoproteins; distribution among density fractions. FEBS let. 1979;102;183-186.
  9. Shi W, Anticardiolipin antibodies block the inhibition by b2-glycoprotein I of the factor Xa generating activity of platelets. Thromb. Haemost. 1993;70;342-345.
  10. Tincani A, Rebaioli C, Andreoli L et al. Neonatal effects of maternal antiphospholipid syndrome. Surrent Rheumatology Reports. 2009;11; 70-76.
  11. Andreoli L, Fredi M, Nalli C et. al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. Journal of Autoimmunity. 2012. 38; 2-3; J197-J208.
  12. Rand JH, Wu XX, Guller S et al. Antiphospholipid immunoglobulin G antibodies reduce annexin V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am. J. Obstet. Gynecol. 1997;177;918-923.
  13. Meroni P, Raschi E, Testoni C, Borghi MO.Endothelial cell activation by antiphospholipid antibodies. Clin. Immunol. 2004;112;169-174
  14. Hamid C, Norgate K, D’Cruz DP et. al. Anti beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes involved in primary antiphospholipid syndrome. Ann. Rheum. Dis. 2007;66;1000-1007.
  15. Branch DW, Silver RM, Blackwell JL et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstetrics and Gynecology, 1992, 80(4):614-620.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.